These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Clinical studies on chronic diabetic nephropathy and recent data concerning prevention of risks of nephropathy and cardiovascular diseases]. Esnault V Nephrol Ther; 2006 May; 2 Suppl 3():S193-6. PubMed ID: 17370850 [TBL] [Abstract][Full Text] [Related]
23. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836 [TBL] [Abstract][Full Text] [Related]
24. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction. Azadpour M; Lamas GA Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434 [TBL] [Abstract][Full Text] [Related]
26. Towards 2001: will ACE inhibitors have a role in atherosclerosis treatment? Sharpe N Int J Clin Pract Suppl; 1998 May; 94():26-31. PubMed ID: 9926442 [TBL] [Abstract][Full Text] [Related]
27. Ramipril. Smith WH; Ball SG Int J Clin Pract; 2000 May; 54(4):255-60. PubMed ID: 10912316 [TBL] [Abstract][Full Text] [Related]
28. Have angiotensin receptor blockers lived up to expectations? Fitchett D Can J Cardiol; 2005 May; 21(7):569-75. PubMed ID: 15940354 [TBL] [Abstract][Full Text] [Related]
29. [Treatment by angiotensin converting enzyme inhibitors after myocardial infarction. What did the clinical trials teach us?]. Guéret P; Garot J; Barnier P Arch Mal Coeur Vaiss; 1996 Aug; 89 Spec No 3():33-8. PubMed ID: 8949316 [TBL] [Abstract][Full Text] [Related]
30. [The ACE inhibitor spirapril in chronic renal failure, hypertension and diabetic nephropathy]. Elliot HL Ter Arkh; 2000; 72(10):78-82. PubMed ID: 11220886 [TBL] [Abstract][Full Text] [Related]
31. [Role of angiotensin-converting enzyme inhibitors in the treatment of heart failure in the 21st century]. Gibelin P Arch Mal Coeur Vaiss; 2002 Feb; 95 Spec 4(5 Spec 4):41-5. PubMed ID: 11933555 [TBL] [Abstract][Full Text] [Related]
33. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients. Vijan SG J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392 [TBL] [Abstract][Full Text] [Related]
34. Use of the ACE inhibitor zofenopril in the treatment of ischemic heart disease. Buikema H Expert Rev Cardiovasc Ther; 2006 Sep; 4(5):631-47. PubMed ID: 17081085 [TBL] [Abstract][Full Text] [Related]
35. Angiotensin II type 1 receptor blockade: a new development in cardiovascular pharmacology. Leary AC; MacDonald TM Int J Clin Pract; 1998 Oct; 52(7):475-81. PubMed ID: 10622089 [TBL] [Abstract][Full Text] [Related]
36. [Angiotensin-converting enzyme inhibitors. Principles and rules of their use]. Juillière Y Rev Prat; 2001 Sep; 51(14):1601-7. PubMed ID: 11757278 [No Abstract] [Full Text] [Related]
37. ACE inhibitors: a patient lifeline? Ball S; Hall A Practitioner; 1994 Dec; 238(1545):848-52. PubMed ID: 7838821 [No Abstract] [Full Text] [Related]
38. Factors to consider in selecting an angiotensin-converting-enzyme inhibitor. Waugh WJ Am J Health Syst Pharm; 2000 Oct; 57 Suppl 1():S26-30. PubMed ID: 11030020 [TBL] [Abstract][Full Text] [Related]
39. Angiotensin-converting enzyme inhibitors. Brown NJ; Vaughan DE Circulation; 1998 Apr; 97(14):1411-20. PubMed ID: 9577953 [TBL] [Abstract][Full Text] [Related]
40. The role of ACE inhibitors in mild heart failure. de Bono D Practitioner; 1994 Jan; 238(1534):66-9. PubMed ID: 8108336 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]